Despite posting a double-digit drop in first-quarter revenues, Affymetrix executives said last week that they are "optimistic" about the firm's future, pointing to growth in demand for genotyping arrays.

Affy reported last week that revenues for the three months ended March 31 dropped 12 percent to $65.2 million from $73.7 million a year ago. Much of the falloff was attributable to a "precipitous" decline in expression array sales, which plummeted 20 percent year over year as researchers continue to transition to next-generation sequencing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.